Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer

European Journal of Cancer Part A

Volumn 32, Issue 12, 1996, Pages 2173-2176

  Borner, M M ^a   Bacchi, M ^b   Castiglione, M ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

breast cancer; hormonal treatment; locoregional recurrence; menopausal status; metastases; tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN;

EID: 2042511786     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00227-4     Document Type: Article

References (18)

1. 1. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995, 13, 513-529.
2. 2. The Early Breast Cancer Trialists' Collaborative group: systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992, 339, 1-15, 71-84.
3. 3. Sunderland M, Osborne C. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991, 9, 1283-1297.
4. 4. Houghton J, Riley D, Baum M. The Nolvadex Adjuvant Trial Organisation (NATO) and the Cancer Research Campaign (CRC). Trials of adjuvant tamoxifen therapy on behalf of the CRC Breast Cancer Trials Group. In Jordan VC, ed. Long-term Tamoxifen Treatment for Breast Cancer. Madison, University of Wisconsin Press, 1994, 93-113.
5. 5. Sasco AJ. Tamoxifen and menopausal status: risks and benefits. Lancet 1996, 347, 761 (letter).
6. 6. Recht A, Hayes DF. Specific sites and emergencies: local recurrence. In Harris JR, Hellman S, Henderson IC, et al., eds. Breast Diseases. Philadelphia, Lippincott, 1991, 527-540.
7. 7. Borner M, Bacchi M, Goldhirsch A, et al. First isolated loco-regional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994, 12, 2071-2077.
8. 8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
9. 9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-167.
10. 10. Cox DR. Regression models and life tables. J R Stat Soc B 1972, 34, 187-220.
11. 11. Simon R. Statistical tools for subset analysis in clinical trials. In Scheurten H, Kay R, Baum M, eds. Recent Results in Cancer Research, Vol 111. Berlin, Springer-Verlag, 1988, 55-66.
12. 12. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16, 1141-1154.
13. 13. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, 170-174.
14. 14. Gelman R, Gelber R, Henderson I, Coleman C, Harris J. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1994, 8, 548-555.
15. 15. Simon R. Discovering the truth about Tamoxifen. Problems of multiplicity in statistical evaluation of biomedical data. J Natl Cancer Inst 1995, 9, 627-629.
16. 16. Harris JR, Gelman R. What have we learned about risk factors for local recurrence after breast-conserving surgery and irradiation? J Clin Oncol 1994, 12, 647-649 (editorial).
17. 17. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320, 479-484.
18. 18. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983, 1, 227-241.